CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
RelieVRx +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05546749
NCT05546749N/ACompleted
CompareCT.gov

Virtual Reality Treatment in a Methadone Maintenance Treatment Program for Chronic Pain and Opioid Use Disorder

Albert Einstein College of Medicine·interventional·Posted Sep 21, 2022·Updated Mar 5, 2025

In Brief

A clinical study evaluating RelieVRx and Sham VR for Chronic Pain and Opioid Use Disorder. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This is a pilot feasibility study of a virtual reality device for patients with co-morbid chronic pain and opioid use disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain, Opioid Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
2023202420252026
First PostedSep 21, 2022
Enrollment StartFeb 8, 2023
Primary CompletionJul 12, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.8 years ago

Interventions

RelieVRxdevice

The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.

Sham VRdevice

The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.